Mirum Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $77.9M | $69.2M | $69.6M | $47.7M | $37.5M | $31.6M | $27.9M | $18.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $49.2M | $45.6M | $46.2M | $36.5M | $32.9M | $30.2M | $26.5M | $22.5M |
| Operating Income | $-24.2M | $-26.5M | $-32.6M | $-25.1M | $-24.3M | $-27.1M | $-34.2M | $-32.9M |
| Operating Margin | -31.1% | -38.2% | -46.8% | -52.7% | -64.7% | -85.9% | -122.4% | -175.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-24.0M | $-24.7M | $-35.4M | $-23.3M | $-73.7M | $-29.9M | $-36.3M | $-35.7M |
| Income Tax Expense | $635.0K | $624.0K | $225.0K | $249.0K | $316.0K | $201.0K | $140.0K | $13.0K |
| Net Income | $-24.6M | $-25.3M | $-35.7M | $-23.6M | $-74.0M | $-30.1M | $-36.4M | $-35.7M |
| Net Margin | -31.6% | -36.5% | -51.3% | -49.4% | -197.5% | -95.4% | -130.5% | -190.1% |
| EPS (Basic) | $-0.52 | $-0.54 | $-0.69 | $-0.57 | $-1.94 | $-0.80 | $-0.98 | $-1.02 |
| EPS (Diluted) | $-0.52 | $-0.54 | $-0.69 | $-0.57 | $-1.94 | $-0.80 | $-0.99 | $-1.02 |
| Shares Outstanding (Basic) | 47.2M | 46.9M | 40.9M | 41.1M | 38.1M | 37.7M | 33.8M | 34.9M |
| Shares Outstanding (Diluted) | 47.2M | 46.9M | 40.9M | 41.1M | 38.1M | 37.7M | 34.0M | 34.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |